Croatian Perspectives for Person Centered Care in Oncology

Main Article Content

Zoran Rakusic
Ana Misir Krpan
Vesna Bisof
Kristina Ruza Samardjic


In the last decade there has been a strong development and new discoveries in the field of oncology. Molecular biology has undergone the greatest evolution and this makes difficult for clinicians to follow closely. In fact, among thousands of new discoveries, only few have truly led to clear benefit for patients. When studying a person on a molecular level, we must never forget the person as a whole.There are more treatment options that should be tailored to each patients’ characteristics and wishes. Therefore, in developing person cantered care we should be attentive to the critical features of person centered medicine, i.e., ethical commitment, cultural sensitivity, holistic scope, relational focus, individualized care, common ground for diagnosis and care, people-centered organization of services, and person-centered health education and research. This paper summarized Croatian efforts to develop person-centered care for oncological conditions.

Article Details

Regular Articles
Author Biography

Zoran Rakusic, University Hospital Centre Zagreb

Head of clinical ward for head and neck oncology


. Mezzich JE, Kirisci L, Salloum IM (2011) Technical Report from the INPCM-WHO Project on Developing Measures to Assess Progress towards People-centered Care. International College of Person Centered Medicine, New York.

. Unger K. (2014). Integrative Radiation Systems Biology. Radiation Oncology 9(1):21.

. Lambin, P., Roelofs, E., Reymen, B., Velazquez, E.R., Buijsen, J., Zegers, C.M., Carvalho, S., Leijenaar, R.T., Nalbantov, G., Oberije, C., et al. (2013). 'Rapid Learning health care in oncology' - an approach towards decision support systems enabling customised radiotherapy'. Radiotherapy and Oncology 109(1):159-64.

. Howlader, N., Noone, A.M., Krapcho, M., et al. (2013) SEER Cancer Statistics Review, 1975-2010, National Cancer Institute. Bethesda, MD,, based on November 2012 SEER data submission, posted to the SEER web site, 2013.

. Slamon, D., Leyland-Jones, B., Shak, S., et al. (1998). Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer markedly increases anticancer activity: a randomized, multinational controlled Phase III trial. Proc of ASCO #377, 17:98A.

. Van Cutsem, E., Köhne, C.H., Hitre, E., et al. (2009). Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer. New England Journal of Medicine 360:1408-1417.

. Chapman, P.B., Hauschild, A, Robert, C., et al. for the BRIM-3 Study Group(2011). Improved survival with vemurafenib in melanoma with BRAF V600E mutation. New England Journal of Medicine 364:2507-2516.

. Oken, M.M., Creech, R.H., Tormey, D.C., Horton, J., Davis, T.E., McFadden, E.T., Carbone, P.P.(1982). Toxicity and Response Criteria of the Eastern Cooperative Oncology Group. American Journal of Clinical Oncology 5:649-655.

. Schag, C.C., Heinrich, R.L., Ganz, P.A. (1984). Karnofsky performance status revisited: Reliability, validity, and guidelines. Journal of Clinical Oncology 2:187-193.

. Grassi, L. (2013). Quam bene vivas referre: curing and caring in psycho-oncology. Psychooncology 22(8):1679-87.

. Mezzich, J.E., Snaedal, J., van Weel, C., Botbol, M., Salloum, I.(2011). Introduction to person-centred medicine: from concepts to practice. Journal of Evaluation in Clinical Practice. 17(2):330-2.

. Cheng, S.Y., Dy, S., Huang, S.B., Chen, C.Y., Chiu, T.Y. (2013). Comparison of proxy ratings of main family caregivers and physicians on the quality of dying of terminally ill cancer patients. Japanese Journal of Clinical Oncology 43(8):795-804.

. Hamaker, M.E., Stauder, R., van Munster, B.C. (2014). On-going clinical trials for elderly patients with a hematological malignancy: are we addressing the right end points? Annals of Oncology, Jan 23, . [Epub ahead of print]